Press Releases

BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced its collaboration with VELL Health, a technology leader in wellness and holistic health, to introduce a groundbreaking holistic health and wellness application for people with Type 2 Diabetes in Guyana. This innovative initiative is part of Guyana's nationwide pilot program for diabetes clinics which aims to improve healthcare by leveraging mobile technology, data sciences,

Anbio, a leading provider of innovative diagnostic solutions, proudly presents its comprehensive RT-PCR solution that encompasses both pharmacogenomic and non-pharmacogenomic applications. Anbio molecular diagnostic test menu spans multiple clinical applications including healthcare-associated infections, critical infectious disease, sexual health, virology, pharmacogenomics, and oncology. Anbio molecular diagnostic tests can be employed in institutions of any size, from small medical clinics

TransCure bioServices, a humanized mouse model CRO, has partnered with Preclina Inc., a South Korean preclinical CRO specializing in autoimmune and inflammatory diseases. The partnership significantly expands TransCure’s reach into the APAC region, while also bolstering its service offerings to further enhance the quality of its research results. Biotechnology and pharmaceutical companies in the region will now have better access to a selection of the most advanced mouse models, as well

Evogene Ltd. a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, is proud to announce the latest addition to its ChemPass AI tech-engine – a breakthrough technology for target-protein discovery. The integration of TargetSelector, a new application that streamlines target-protein discovery for active molecule identification, assists researchers in finding suitable target proteins for new produc

SomaLogic Operating Co. Inc. a leader in data-driven proteomics technology, today announced its partnership with Dante Genomics, a global leader in genomics and precision medicine, to offer a comprehensive solution for proteomics testing at scale in Europe. Dante will be the first SomaLogic authorized site in Italy. "Over the past seven years, Dante has been intensely focused on enhancing the clinical utility of the genome, and in partnering with SomaLogic, we will now work tog

Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. a global leader in generic and innovative medicines and Alvotech a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that they have agreed to expand their existing strategic partnership agreement. Teva will also acquire subordinated convertible bonds to be issued by Alvotech. The partners continue working closely on

Polpharma Biologics, an international biotech company dedicated to the development and manufacturing of biosimilars, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), adopted a positive opinion regarding granting marketing authorization for natalizumab - a first-of-a-kind biosimilar for the treatment of multiple sclerosis. Biosimilar natalizumab was developed by Polpharma Biologics and will be commercialized by its collabora

Sathgen Therapeutics, a division of India's leading chemical conglomerate, Godavari Biorefineries Limited has announced the completion of the first cohort of a Phase 1 clinical trial for its first-in-class new chemical entity, MSP008-22. The clinical trial program is managed by Clinexel Life Sciences, a renowned contract research organization in the healthcare industry. Sathgen Therapeutics aims to develop MSP008-22 for hard-to-treat cancers, starting with triple negative breast

TVM Capital Life Science a leading international venture capital firm focused on investments in life sciences innovation, together with specialty pharma company, Tillotts Pharma  today announced that the companies will jointly invest up to USD 28 million in the newly formed U.S.-based biotechnology company, Mage Biologics Inc. ("Mage Bio"). TVM will invest with its fund TVM Life Science Innovation II SCSp ("TVM LSI II") and will provide strategic advice to Mage Bio, w

RenovoRx, Inc.a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd a clinical-stage immuno-oncology company, today announced a strategic research collaboration to optimize the delivery of Imugene's oncolytic virus therapy with RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors. "We believe the synergy between RenovoRx's trans-arterial drug delivery system